TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2491883
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion schedule of ifosfamide
Study: 2491883
Drug: Performance score
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Performance score 0-2 prior to chemotherapy
Study: 2491883
Drug: Performance score
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Performance score 0-1 prior to chemotherapy
Study: 31399883
Drug: Dry syrup
Normalized name: Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry syrup formulation (2%, 1g containing 20mg of memantine hydrochloride)
Study: 31399883
Drug: Film-coated tablet
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Film-coated tablet (reference product)
Study: 17640415
Drug: Carob fibre
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carob fibre (50 g)
Study: 10095691
Drug: Self-administration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of medication
Study: 10095691
Drug: Patient-friendly drug
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient-friendly drug leaflets
Study: 7924772
Drug: Insulin-treated pregnant
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-treated pregnant women
Study: 3094403
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HFJV with Intermittent Positive Pressure Ventilation (CV)
Study: 26663590
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (200 mcg every 12 h)
Study: 26663590
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin (starting from 6 mU/min to maximum 40 mU/min)
Study: 22979982
Drug: Amantadine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (100 mg twice daily) for 4 weeks
Study: 22979982
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) (500 mg once daily) for 4 weeks
Study: 20223132
Drug: Intracapsular anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracapsular anesthesia (8 mL of 2% lidocaine) - Group B
Study: 20223132
Drug: Oral clorazepate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral clorazepate dipotassium (5 mg one hour before biopsy) - Group C
Study: 18672400
Drug: PBT2 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBT2 50 mg
Study: 25223369
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg once daily
Study: 18389900
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg once daily (in patients not receiving stavudine)
Study: 11524351
Drug: 9 mL
Normalized name: ethanol 6.9 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mL of 2% lidocaine
Study: 9266230
Drug: Doxazosin (1-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (1-4 mg o.d.)
Study: 8395761
Drug: Captopril, 6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril, 6.25 mg orally
Study: 8395761
Drug: Enalapril, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril, 2.5 mg orally
Study: 8395761
Drug: Perindopril, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril, 2 mg orally
Study: 8395761
Drug: Enalaprilat, 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat, 1.5 mg intravenously
Study: 8395761
Drug: Perindoprilat, 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindoprilat, 1.0 mg intravenously
Study: 23914733
Drug: Combined VR
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined VR and upper limb conventional (ULC) therapy
Study: 23914733
Drug: ULC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ULC therapy alone
Study: 16952209
Drug: Gentamicin-collagen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin-collagen treatment
Study: 14610236
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF, filgrastim) 300 microg
Study: 14610236
Drug: Flurbiprofen 50
Normalized name: flurbiprofen 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 50 mg (oral) before G-CSF injection
Study: 11391341
Drug: Recombinant granulocyte
Normalized name: Glycosylated recombinant granulocyte colony stimulating factor
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant granulocyte colony-stimulating factor (rG‐CSF) in subgroups '<2000 g' or 'neutropenia'
Study: 2426590
Drug: Intravenous gamma
Normalized name: Gamma Cyclodextrin
DrugBank: Gamma cyclodextrin (DB19173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gamma globulin plus aspirin
Study: 26926419
Drug: Multimodal drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal drug injection
Study: 26926419
Drug: No multimodal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No multimodal drug injection (control group)
Study: 20649979
Drug: Highly diluted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly diluted homeopathic drug (potency C12 = 1024), Dose: 5 globules taken 5 times per day over a maximum period of 5 days
Study: 7826080
Drug: KW-2307 (KW)
Normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KW-2307 (KW) 25 mg/m2
Study: 7826080
Drug: Vindesine (VDS)
Normalized name: vindesine
DrugBank: Vindesine (DB00309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vindesine (VDS) 3 mg/m2
Study: 7826080
Drug: KW-2307 (KW)
Normalized name: KW-7158
DrugBank: KW-7158 (DB05498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KW-2307 (KW) with cisplatin (CDDP) 80 mg/m2
Study: 7826080
Drug: Vindesine (VDS)
Normalized name: vindesine
DrugBank: Vindesine (DB00309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vindesine (VDS) with cisplatin (CDDP) 80 mg/m2
Study: 1784628
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg miglitol
Study: 7821886
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg acarbose
Study: 28118174
Drug: Fesoterodine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine therapy (4-8 mg daily, n = 322)
Study: 26023772
Drug: Clear water
Normalized name: Sunmark Bandage Clear Watershield
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear water with soap during a daily shower
Study: 17076980
Drug: Colesevelam HCl
Normalized name: colesevelam HCl
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colesevelam HCl 3.8 g/day plus ezetimibe 10 mg/day
Study: 9540024
Drug: Miglitol (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglitol (50, 100, 150, 200 mg t.i.d.)
Study: 7972294
Drug: Caffeine treatment
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine treatment (overall)
Study: 1096904
Drug: Indometacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indometacin (100 g/day)
Study: 22228279
Drug: Provocative discography
Normalized name: OCTINOXATE 0.072 g in 1 g TOPICAL LIPSTICK [EFFET PARFAIT ROUGE AMPLIFIER AMPLIFYING SPF 15 (ROUGE PROVOCATION) - RED]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Provocative discography plus intradiscal injection of dexamethasone (5 mg)
Study: 22228279
Drug: Intridiscal injection
Normalized name: CHYMOPAPAIN 2nKatU/ML INTRADISCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intridiscal injection of saline (placebo)
Study: 17622942
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate (Copaxone) immunotherapy
Study: 15683662
Drug: External beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam irradiation (EBI) 6 MV photons, total dose 24 Gy in six fractions in 2 weeks
Study: 16011059
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no radiation therapy)
Study: 12095383
Drug: Nevirapine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine (200 mg oral dose to women after onset of labor and 2 mg/kg oral dose to newborns between 48 and 72 hours after birth)
Study: 27755050
Drug: Standard organization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard organization of treatment (n = 21)
Study: 19779025
Drug: Olanzapine orally
Normalized name: Olanzapine Orally Disintegrating Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine orally disintegrating tablets (ODT) 10 mg o.d. for 8 days
Study: 19779025
Drug: Olanzapine standard
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine standard oral tablets (OST) 10 mg o.d. for 8 days
Study: 17687152
Drug: Donepezil 5
Normalized name: donepezil 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 5 mg orally every morning for 7 days
Study: 10673975
Drug: Remission-induction therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remission-induction therapy followed by one consolidation course, with randomisation between autologous bone marrow transplantation (ABMT) and a second intensive consolidation course.
Study: 10673975
Drug: Full protocol
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full protocol treatment completion.
Study: 8608488
Drug: Granisetron (GRA)
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron (GRA) 3 mg i.v.
Study: 8608488
Drug: Ondansetron (OND)
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron (OND) 24 mg i.v.
Study: 8608488
Drug: Tropisetron (TRO)
Normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron (TRO) 5 mg i.v.
Study: 2012289
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine 0.75 ml.kg‐1 with morphine 0.05 mg.kg‐1
Study: 2012289
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine 0.75 ml.kg‐1
Study: 6128270
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of 16-phenoxy-omega-17,18,19,20-tetranor-PGE2 methyl sulphonylamide
Study: 6128270
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg of 16-phenoxy-omega-17,18,19,20-tetranor-PGE2 methyl sulphonylamide
Study: 27044282
Drug: Planned invasive
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Planned invasive treatment
Study: 27044282
Drug: Planned conservative
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Planned conservative treatment
Study: 23376318
Drug: Corticosteroid injections
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injections (4 quadrant injections of 0.5 mL triamcinolone, 40 mg/mL, n = 29)
Study: 20675729
Drug: Amniotic membrane
Normalized name: Amniotic Membrane Human Ophthalmic Sheet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amniotic membrane transplantation in addition to conventional medical therapy
Study: 19473600
Drug: Fesoterodine 8
Normalized name: fesoterodine 8 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine 8 mg administered in a fed state (after a high-fat, high-calorie breakfast)
Study: 19473600
Drug: Fesoterodine 8
Normalized name: fesoterodine 8 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine 8 mg administered in a fasted state
Study: 18039018
Drug: Topical terbinafine
Normalized name: terbinafine Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical terbinafine (various formulations)
Study: 9888867
Drug: 7 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 g/d omega-3 fatty acids for 4 weeks
Study: 9888867
Drug: 7 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 g/d omega-6 or omega-9 fatty acids for 4 weeks
Study: 7718754
Drug: Enalaprilat, 0.06
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat, 0.06 mg/kg
Study: 1851142
Drug: Recombinant alpha‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant alpha‐2a interferon (Roferon‐A) at a dose of 5 MU/m2 S.C. three times a week and cisplatinum at dose levels of 15, 20, 25, 33, and 42 mg/m2/week given intravenously
Study: 29537978
Drug: Transdermal rivastigmine
Normalized name: rivastigmine Transdermal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal rivastigmine (9.5 mg/10 cm daily)
Study: 29537978
Drug: Oral rivastigmine
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral rivastigmine (6 mg twice daily)
Study: 26507721
Drug: Dulaglutide 1.5
Normalized name: dulaglutide 1.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dulaglutide 1.5 mg dose
Study: 21077306
Drug: BPB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPB with 0.2% ropivacaine at an infusion rate of 6 ml x hr(‐1) (n = 12)
Study: 21077306
Drug: BPB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPB with 0.2% ropivacaine at an infusion rate of 4 ml x hr(‐1) (n = 12)
Study: 21077306
Drug: BPB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPB with 0.2% ropivacaine at an infusion rate of 8 ml x hr(‐1) (n = 5)
Study: 15906030
Drug: Three cycles
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three cycles of chemotherapy prior to surgery and three cycles after surgery (Group 1)
Study: 15906030
Drug: Six cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six cycles of chemotherapy prior to surgery (Group 2)
Study: 15906030
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (six cycles)
Study: 10505539
Drug: Hirudin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirudin (0.4 mg/kg bolus, then 0.15 mg/kg per hour infusion)
Study: 10505539
Drug: Heparin (5,000-U
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (5,000-U bolus, then 15-U/kg per hour infusion)
Study: 6374402
Drug: Oral lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lithium started at the time of biopsy‐proven hypoplasia
Study: 30536081
Drug: Roflumilast 250
Normalized name: ROFLUMILAST 250MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roflumilast 250 μg daily
Study: 30536081
Drug: Roflumilast 100
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Roflumilast 100 μg daily
Study: 18556964
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) at a dosage of 0.067 mg/kg/day
Study: 16087818
Drug: Full starting
Normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Full starting dose of levothyroxine (1.6 mug/kg)
Study: 16087818
Drug: Low starting
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low starting dose of levothyroxine (25 mug, increased every 4 weeks)
Study: 12452231
Drug: Morphine 1
Normalized name: morphine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 1 mg and droperidol 0.0625 mg
Study: 10358538
Drug: Standardised protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised protocol administered by senior nurses
Study: 10649811
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (CEE), 0.625 mg/d
Study: 7807658
Drug: CEE, 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE, 0.625 mg/d plus cyclic medroxyprogesterone acetate (MPA), 10 mg/d for 12 d/mo
Study: 7807658
Drug: CEE, 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE, 0.625 mg/d plus consecutive MPA, 2.5 mg/d
Study: 7807658
Drug: CEE, 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE, 0.625 mg/d plus cyclic micronized progesterone (MP), 200 mg/d for 12 d/mo
Study: 8369511
Drug: Corticosteroids (prednisone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (prednisone, 60 mg/day for 7 days, followed by tapering over 14 days)
Study: 29792226
Drug: Regular occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular occupational therapy
Study: 25818388
Drug: Conventional control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional control therapy
Study: 22684431
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg abatacept plus MTX
Study: 22684431
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg abatacept plus MTX
Study: 16800349
Drug: ICL670 (deferasirox)
Normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ICL670 (deferasirox) at a dose of 20 to 40 mg/kg
Study: 15138373
Drug: Osteopathic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic treatment (manual techniques including parietal, visceral, and craniosacral techniques)
Study: 15138373
Drug: Orthopedic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthopedic treatment (chiropractic techniques, antiphlogistics, and cortison injections)
Study: 9655732
Drug: salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: salmeterol 50 microg twice daily (BDP400+salm)
Study: 9655732
Drug: beclomethasone 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: beclomethasone 200 microg twice daily (BDP800)
Study: 9655732
Drug: placebo (BDP400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (BDP400) in addition to beclomethasone 200 microg twice daily
Study: 6097137
Drug: Atracurium 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.4 mg/kg
Study: 27312053
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy with cisplatin (25 mg/m² on days 1 and 8), etoposide (60 mg/m² on days 1-3), and irinotecan (90 mg/m² on day 8) for five 2-week courses.
Study: 27312053
Drug: Topotecan (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan (1.0 mg/m² on days 1-5, every 3 weeks) for four courses.
Study: 27312053
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy group
Study: 20636485
Drug: l‐NMMA (NO
Approvals — FDA: no, EMA: no, PMDA: no
Description: l‐NMMA (NO synthase inhibitor)
Study: 20636485
Drug: Phenylephrine (α‐receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (α‐receptor agonist)
Study: 20178604
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy (approximately 10,000 lux for two half-hour sessions daily)
Study: 20178604
Drug: Placebo (approximately
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (approximately 300 lux for two half-hour sessions daily)
Study: 18502107
Drug: Lignan complex
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignan complex (500 mg/d of secoisolariciresinol diglucoside)
Study: 15918387
Drug: Propacetamol 2
Normalized name: 1,2,3-PROPANETRIOL, 2-(4-AMINOBENZOATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propacetamol 2 g + Ketoprofen 100 mg
Study: 10085472
Drug: melatonin (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: melatonin (various doses)
Study: 31077798
Drug: AOMI+PAIN (AOMI
Approvals — FDA: no, EMA: no, PMDA: no
Description: AOMI+PAIN (AOMI during hypertonic saline injection)
Study: 31077798
Drug: PAIN (rest
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAIN (rest for 10 minutes after hypertonic saline injection)
Study: 26293163
Drug: Tabalumab 120
Normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tabalumab 120 mg every 2 weeks (120 Q2W)
Study: 26293163
Drug: Tabalumab 120
Normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tabalumab 120 mg every 4 weeks (120 Q4W)
Study: 19733721
Drug: Naproxcinod 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxcinod 750 mg twice daily
Study: 19733721
Drug: Naproxcinod 375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxcinod 375 mg
Study: 17531690
Drug: Intracameral cefuroxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracameral cefuroxime prophylaxis at 1 mg in 0.1 mL normal saline
Study: 15262827
Drug: Aprotinin (2x10(6)
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprotinin (2x10(6) KIU in pump prime, 2x10(6) KIU loading dose, followed by 0.5x10(6) KIU/h
Study: 9850898
Drug: Topical tetracaine
Normalized name: tetracaine Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tetracaine 0.5% plus intracameral lidocaine 1%
Study: 9850898
Drug: Topical tetracaine
Normalized name: tetracaine Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tetracaine 0.5% plus intracameral BSS
Study: 3377945
Drug: pethidine 1
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pethidine 1 mg kg‐1 i.v.
Study: 3377945
Drug: pethidine 1
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pethidine 1 mg kg‐1 i.m.
Study: 3377945
Drug: pethidine 1
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pethidine 1 mg kg‐1 rectally
Study: 28460544
Drug: Early low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early low dose aprotinin
Study: 28460544
Drug: Late low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late low dose aprotinin
Study: 25441397
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg daily for 12 weeks